14 
However, I have established a committee at the NIH, chaired by 
Dr. Richard Krause, Director, NIAID, to study and recommend, if 
necessary, safety standards for other NIH-supported research involving 
actual or potential biohazards. The preliminary report is expected 
shortly, and I will keep the Committee informed of the progress on 
this NIH review. 
Regulation of just the research aspects of recombinant DNA 
techniques presents a problem because of the difficulty in determining 
the border between research and pilot production. Therefore, the 
Committee recommends that regulation cover the production or use of 
recombinant DNA molecules. Such language would include research 
activity, and makes immaterial possible concerns whether a given 
activity constitutes research, pilot production, or manufacture. 
The Committee recommends that the Secretary, in specific instances, in 
consultation with appropriate regulatory agencies, be allowed to determine 
the nature of the activity and should defer to a regulatory body that the 
Secretary determines is better empowered and equipped to deal with it. 
There was general agreement by the Committee that registration of 
projects involving the use or production of recombinant DNA molecules 
was necessary. The Committee also recommends that facilities be licensed 
and that the terms of the license include acceptance of responsibility 
for the particular activities and individuals at the facility. The 
Committee concluded that licensure of the facility and registration of 
projects would be more feasible and would more adequately meet the needs 
[ 373 ] 
